Células madre

Carboxylesterase-IN-2 is a potent Carboxylesterase Notum inhibitor (IC50 <= 10 nM).Carboxylesterase-IN-2 has potential for the study of cancer diseases.

MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.

IWP-O1 is a highly potent Porcupine (Porcn) inhibitor (EC50: 80 pM), effectively suppresses the phosphorylation of Dvl2/3 and LRP6 in HeLa cells.

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human TNNI3/cTn-I. Samples (or Standards) are added to the micro ELISA plate wells and combined with the specific antibody and biotinylated detection antibody specific for Human TNNI3/cTn-I. Then Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human TNNI3/cTn-I, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm. The OD value is proportional to the concentration of Human TNNI3/cTn-I. You can calculate the concentration of Human TNNI3/cTn-I in the samples by comparing the OD of the samples to the standard curve.

Dynarrestin inhibits cytoplasmic dynein 1/2, preventing microtubule sliding without affecting ATP hydrolysis or ciliogenesis.

Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.

SANT 2 is a Hedgehog (Hh) signaling pathway antagonist with potential anti-inflammatory and anti-cancer activities.

Wnt pathway inhibitor 3 is a potent AC1 inhibitor with an IC50 value of 45 nM.Wnt pathway inhibitor 3 has antiproliferative activity and can be used in studies

E2012 is a γ-secretase modulator (GSM).

NRX-103095 increases β-catenin binding to SCFβ-TrCP E3 ligase; EC50 is 163 nM for pSer33/Ser37 affinity boost.

IMR-1A is the metabolite of IMR-1 which is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.

JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].

CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.

KY-05009 blocks TGF-β1 EMT in lung cancer cells, inhibits TNIK, Wnt genes, induces apoptosis, and is an ATP-competitive TNIK inhibitor (Ki = 100 nM).

Neocucurbitacin A (compound 7), a STAT3 inhibitor extracted from the pericarp of Aquilaria crassna, serves as a potential agent for anticancer research [1].

LGK974 (NVP-LGK974) is a selective PORCN inhibitor that blocks Wnt signaling, used in metastatic colorectal and head/neck cancer trials. IC50: 0.4 nM.

AZD2858 is a selective GSK-3 inhibitor, inhibiting tau phosphorylation at the S396 site and activating Wnt signaling pathway.

Epiblastin A inhibits CK1, targets its isoenzymes, and converts EpiSCs to cESCs.

SMANT hydrochloride (N-(4-bromophenyl)-3-(3,5-dimethylpiperidin-1-yl)propanamide hydrochloride) is an antagonist of Smoothened accumulation.

Disitertide acetate: a TGF-β1 and PI3K blocker, promotes apoptosis; inhibits receptor interaction.

Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.

GSK180736A: GRK2 inhibitor (IC50 0.77µM), >100x selectivity vs GRKs, weak at PKA (IC50 30µM), strong vs ROCK1 (IC50 100nM).

Anti-5T4/TPBG Antibody (9P872) is an antibody targeting 5T4/TPBG. Anti-5T4/TPBG Antibody (9P872) can be used in ELISA, FCM.

JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.

MSC-4106, an oral YAP/TAZ-TEAD inhibitor, blocks TEAD1/3 auto-palmitoylation and suppresses NCI-H226 tumors.

STAT6-IN-3 (Compound 18a) serves as an inhibitor of STAT6 with an IC50 value of 44 nM, specifically targeting the Src Homology 2 (SH2) domain.

TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others

AR-A014418 (GSK 3β inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor.

Aloisine B (AloisineB) inhibited cyclin-dependent kinase and glycogen synthase kinase with IC50 values of 0.85 µM and 0.75 µM, respectively.

ROCK-IN-5 (I-B-37) inhibits kinases like ROCK/ERK/GSK; may aid in cardiac and neuro disease studies.

Rhodblock 6 is a Rho kinase inhibitor, blocking phosphorylated MRLC localization by targeting ROCK activity.

Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and is an effective Wnt agonist.

RhoA-ROCK-IN-1 (Compound b19) is an inhibitor of the RhoA/ROCK pathway. It significantly inhibits cell proliferation, migration, and invasion, while promoting cell apoptosis (apoptosis). RhoA-ROCK-IN-1 exhibits strong anticancer activities by inhibiting the RhoA/ROCK pathway.

CUR61414 is a cell-permeable inhibitor of Hedgehog signaling pathway (IC50 =100-200 nM) and selectively binds to smoothened (Ki = 44 nM).

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.

W1131 TFA is a potent STAT3 inhibitor inducing ferroptosis, effectively halting cancer progression in subcutaneous xenograft, organoid, and PDX models of

SAG 21k is an orally bioactive and potent Hedgehog signaling activator that crosses the blood-brain barrier for the study of cartilage regeneration.

BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)

JAK-IN-5 hydrochloride is a JAK inhibitor [1].

β-catenin modulator IIa-661 is a small molecule inhibitor of the Wnt pathway with antitumour activity.

ETC-159 (ETC-1922159) is a potent, orally available PORCN inhibitor. It inhibits β-catenin reporter activity with an IC50 of 2.9 nM.

Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.

JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.

ARN25068 inhibits GSK-3β, FYN, DYRK1A kinases; acts in sub-micromolar range; combats tau hyperphosphorylation.

Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.

ELN318463 racemate (ELN 318463 racemate) is the racemate of ELN318463 which is an amyloid precursor protein (APP) selective γ-secretase inhibitor.

JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.

SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.

Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human Cys-C, and the Human Cys-C standard plate wells that pre-coated using protein-related techniques are provided separately. Standard/Sample Diluent Buffer or samples are added to the appropriate microtiter plate wells ,then added a HRP-conjugated antibody specific to Human Cys-C. After TMB substrate solution is added, only those wells that contain Human Cys-C and HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.